Recent Events & Catalysts
Arcutis Biotherapeutics, Inc. (ARQT) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup
ChartMill · today
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Benzinga · 5d ago
Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha · 5d ago
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Yahoo · 5d ago
Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary
Yahoo · 5d ago
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38
Benzinga · 5d ago
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Benzinga · 5d ago
Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ...
Yahoo · 5d ago
SEC Filings (90 days)
Results of operations (earnings release), Departure/appointment of directors or officers, Financial statements and exhibits
Filed 2026-08-05 · 6d ago
Departure/appointment of directors or officers, Regulation FD disclosure, Financial statements and exhibits
Filed 2026-07-16 · 26d ago
Submission of matters to a vote of security holders, Other events, Financial statements and exhibits
Filed 2026-06-09 · 63d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.